Preoperative Chemotherapy for Lung Cancer
Author Information
Author(s): Kunitoh H, Kato H, Tsuboi M, Asamura H, Tada H, Nagai K, Mitsudomi T, Koike T, Nakagawa K, Ichinose Y, Okada M, Shibata T, Saijo N
Primary Institution: Japan Clinical Oncology Group
Hypothesis
Is docetaxel combined with cisplatin more effective than docetaxel alone for preoperative chemotherapy in non-small-cell lung cancer?
Conclusion
Docetaxel-cisplatin combination chemotherapy is superior to docetaxel alone in improving disease-free survival and overall survival in patients with early-stage non-small-cell lung cancer.
Supporting Evidence
- The overall response rate was 45% in the cisplatin-docetaxel group compared to 15% in the docetaxel alone group.
- Disease-free survival at 1 year was 78% for the cisplatin-docetaxel group versus 62% for the docetaxel alone group.
- Pathological complete resection was achieved in 95% of patients receiving cisplatin-docetaxel.
Takeaway
Doctors tested two types of chemotherapy before surgery for lung cancer. One type worked much better than the other.
Methodology
Patients were randomly assigned to receive either cisplatin-docetaxel or docetaxel alone before surgery, with disease-free survival as the primary endpoint.
Potential Biases
Potential bias due to lack of blinding and the open-label design.
Limitations
The study was limited by a small sample size and the lack of central confirmation for tumor response assessments.
Participant Demographics
Patients aged 20-74 with untreated, histologically confirmed clinical stage IB/II non-small-cell lung cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website